Mr. Liu Chengwei
Chairman
Mr.Liu Chengwei, was appointed Executive Director of the Company in July 2008, is the Chairman of the Company and is a director of Grand Pharm (China), the principal subsidiary of the Company. Mr. Liu is also a director of Huadong Medicine, the shares of which are listed on the main board of Shenzhen Stock Exchange. Mr. Liu has over 20 years of financial and management experience in the PRC. He joined China Grand Enterprise (“CGE”) in 2001 and is currently the assistant president and director of CGE. Mr. Liu obtained his bachelor degree in International Economics from Peking University and master degree in Business Administration from China Europe International Business School.
Mr. Hu Bo
Deputy Chairman
was appointed executive director of the company in July 2008. Mr. Hu has over 5 years of experience in network project management and property management. He is currently the deputy general manager of a real estate company in the PRC. Mr. Hu holds a bachelor degree in Applied Science & Engineering, Electrical Engineering from University of Toronto. Mr. Hu is a nephew of Mr. Hu Kaijun, the beneficial owner of Outwit, which is the controlling shareholder of the Company.
Dr. Shao Yan
Chief Executive Officer
was appointed executive director of the Company in October 2008. Dr. Shao joined the Company in March 2008 and is the Chief Executive Officer of the Company. Dr. Shao is responsible for overseeing the entire operations and general management of the Company. He has over 20 years of experience in corporate management and venture capital investment. He hold a master’s degree in Business Administration from Guanghua School of Management of Peking University and a doctor degree (PhD) in Management from School of Politics and international Studies of Beijing Normal University.
Dr. Niu Zhanqi
Executive Director
Dr. Niu Zhanqi, aged 49, holds a bachelor degree of science from Nankai University and a doctorate (PhD) degree in pharmacy from Shenyang Pharmaceutical University. Dr. Niu has over ten years of medical research and development experience. He currently serves as Executive President of the Pharmaceutical Management Head Office of China Grand Enterprises Incorporation. He is also Director of Huadong Medicine Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 000963) since June 2016.